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Racial Disparities in Intravenous Recombinant Tissue Plasminogen
Activator Use Persist at Primary Stroke Centers
Hugo J. Aparicio, MD; Brendan G. Carr, MD, MS; Scott E. Kasner, MD; Michael J. Kallan, MS; Karen C. Albright, DO, MPH;
Dawn O. Kleindorfer, MD; Michael T. Mullen, MD
Background-—Primary stroke centers (PSCs) utilize more recombinant tissue plasminogen activator (rt-PA) than non-PSCs. The
impact of PSCs on racial disparities in rt-PA use is unknown.
Methods and Results-—We used data from the Nationwide Inpatient Sample from 2004 to 2010, limited to states that publicly
reported hospital identity and race. Hospitals certiﬁed as PSCs by The Joint Commission were identiﬁed. Adults with a diagnosis of
ischemic stroke were analyzed. Rt-PA use was deﬁned by the International Classiﬁcation of Diseases, 9th Revision procedure code
99.10. Discharges (304 152 patients) from 26 states met eligibility criteria, and of these 71.5% were white, 15.0% black, 7.9%
Hispanic, and 5.6% other. Overall, 24.7% of white, 27.4% of black, 16.2% of Hispanic, and 29.8% of other patients presented to
PSCs. A higher proportion received rt-PA at PSCs than non-PSCs in all race/ethnic groups (white 7.6% versus 2.6%, black 4.8%
versus 2.0%, Hispanic 7.1% versus 2.4%, other 7.2% versus 2.5%, all P<0.001). In a multivariable model adjusting for year, age, sex,
insurance, medical comorbidities, a diagnosis-related group–based mortality risk indicator, ZIP code median income, and hospital
characteristics, blacks were less likely to receive rt-PA than whites at non-PSCs (odds ratio=0.58, 95% CI 0.50 to 0.67) and PSCs
(odds ratio=0.63, 95% CI 0.54 to 0.74) and Hispanics were less likely than whites to receive rt-PA at PSCs (odds ratio=0.77, 95%
CI: 0.63 to 0.95). In the fully adjusted model, interaction between race and presentation to a PSC for likelihood of receiving rt-PA
did not reach signiﬁcance (P=0.98).
Conclusions-—Racial disparities in intravenous rt-PA use were not reduced by presentation to PSCs. Black patients were less likely
to receive thrombolytic treatment than white patients at both non-PSCs and PSCs. Hispanic patients were less likely to be seen at
PSCs relative to white patients and were less likely to receive intravenous rt-PA in the fully adjusted model. ( J Am Heart Assoc.
2015;4:e001877 doi: 10.1161/JAHA.115.001877)
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I ntravenous recombinant tissue plasminogen activator(rt-PA) in acute ischemic stroke has been shown to
improve outcomes in appropriately selected patients when
administered within 4.5 hours.1–3 Despite multiple consensus
guidelines, utilization of rt-PA remains low.4,5 Low treatment
rates are partially explained by delayed hospital arrival, but
provider-level factors may also contribute.6 Utilization of rt-PA
varies further by age, socioeconomic status, hospital size and
case volume, geography, and use of emergency medical
services (EMS).7–12
The past decade has witnessed broad adoption of stroke
systems of care with EMS routing protocols focused on early
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detection of acute ischemic stroke, and prompt transport of
patients to stroke centers.13–15 In December 2003, The Joint
Commission established a national certiﬁcation process for
Primary Stroke Centers (PSCs), based on recommendations
from the Brain Attack Coalition. Hospitals seeking certiﬁca-
tion were required to implement elements such as an acute
stroke team, written care protocols, coordination with EMS,
and creation of a stroke unit.13 Growing evidence indicates
that PSCs utilize more rt-PA than non-PSCs and have lower
mortality rates than noncertiﬁed hospitals.16–20
The role of race in rt-PA utilization is uncertain. Some
previous studies have shown that black patients receive IV rt-
PA 1/5 to 3/4 as often as white patients,8,9,21–24 but other
studies have reported no difference in rates of treatment.25,26
Data for Hispanic patients are also conﬂicting. In one large
nationwide population sample, Nasr et al found lower rates of
rt-PA use for Hispanics.24 In a separate study, Hispanic
patients had equivalent odds of receiving therapy as white
patients.27 Recognizing the limited and inconsistent evidence
concerning stroke and racial disparities, the American Heart
Association/American Stroke Association recommended fur-
ther research on this important topic.28
Using a nationwide hospital administrative database, we
sought to quantify access to PSCs by race and ethnicity and
to compare rt-PA use at PSCs and non-PSCs. We hypothe-
sized that disparities would be reduced at PSCs compared to
hospitals without specialty stroke care.
Methods
Study Design
We performed a retrospective cohort study using data from
the Nationwide Inpatient Sample (NIS) 2004–2010. The NIS,
from the Agency for Healthcare Research and Quality’s
Healthcare Cost and Utilization Project, is the largest publicly
available all-payer inpatient care database.29 The analysis was
limited to data from the 26 states that publicly identiﬁed both
treating hospital and patient race/ethnicity, listed in Table 1.
PSC data, including date of initial certiﬁcation, were obtained
via personal communication from The Joint Commission (Jean
Range, Executive Director of Disease-Speciﬁc Care Program,
The Joint Commission, January 1, 2013).
Patients age ≥18 years with a primary diagnosis of ischemic
stroke deﬁned by International Classiﬁcation of Diseases, 9th
Revision (ICD-9) codes 433.x1, 434.x1, and 436 were identi-
ﬁed. These codes demonstrate >85% positive predictive value
for acute ischemic stroke.30 Patients transferred from other
hospitals were excluded. Hospitalizations with complete data
for all variables were included. Those missing information on
death, sex, length of stay, or expected primary payer were
excluded (Figure 1). Our primary end point, treatment with
intravenous rt-PA, was identiﬁed by International Classiﬁcation
of Diseases, 9th Revision procedure code 99.10.
This study used de-identiﬁed data from an administrative
claims database, so institutional review board approval and
obtaining informed consent were not required.
Demographic Variables
The NIS classiﬁes race/ethnicity uniformly as white, black,
Hispanic, Asian/Paciﬁc Islander, Native American, or other.
Information from hospitals providing the race or ethnicity of
patients are coded from state-speciﬁc data into 1 of the 6 NIS
classiﬁcations. Race and ethnicity are not reported separately
and ethnicity takes precedence over race for coding. Other
patient-level variables included age, sex, year of discharge,
expected primary payer (Medicaid, Medicare, private, or
other), median household income in the patient’s ZIP code,
comorbid conditions (Table 2),31 and an all patient reﬁned-
diagnosis related group (APR-DRG) measure of the risk of
inpatient mortality, which uses diagnoses and procedure
codes to estimate the likelihood of dying during the hospi-
talization as minor, moderate, major, or extreme.32 The all
patient reﬁned-diagnosis related group marker is not speciﬁc
to stroke and does not include a measure of stroke severity.
Hospital-level variables included geographic region (North-
east, Midwest, South, or West), rural or urban location, status
as a teaching hospital (yes/no), and annual ischemic stroke
case volume (<100, 100 to 299, or ≥300).
Table 1. States With Identiﬁable Hospitals and Race/
Ethnicity in the Nationwide Inpatient Sample, 2004–2010
Year
Total
No.
States
No. States w/
Identiﬁable
Hospitals
and Race
States Reporting Hospital Identity
and Race
2004 37 18 AZ, CA, CO, CT, FL, IA, MD, MA,
MO, NH, NJ, NY, NC, RI, UT, VT,
VA, WI
2005 37 17 AZ, CA, CO, CT, FL, IA, MD, MA,
MO, NH, NJ, NY, NC, RI, UT, VT, WI
2006 38 18 AZ, CA, CO, CT, FL, IA, MD, MA, MO,
NH, NJ, NY, NC, RI, UT, VT, VA, WI,
2007 40 18 AZ, CA, CO, CT, FL, IA, MD, MA, MO,
NH, NJ, NY, NC, RI, UT, VT, VA, WI
2008 42 23 AZ, CA, CO, CT, FL, IA, KY, MD, MA,
MO, NV, NH, NJ, NY, NC, OR, PA,
RI, UT, VT, VA, WA, WI
2009 44 23 AZ, CA, CO, CT, FL, IL, IA, KY, MD,
MA, MT, NV, NH, NJ, NY, OR, PA,
RI, UT, VT, VA, WA, WI
2010 45 23 AZ, CA, CO, CT, FL, IL, IA, KY, MD,
MA, MS, MT, NV, NJ, NY, NC, OR,
PA, RI, UT, VT, VA, WI
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Statistical Analysis
Baseline characteristics were described for patients treated at
PSCs and non-PSCs using measures of central tendency
(means, medians) for continuous variables and proportions for
categorical variables. Differences between the groups were
evaluated using Student t test, Wilcoxon rank-sum, and v2
tests, as appropriate. All data were stratiﬁed by race.
Bonferroni correction was used to correct for multiple
comparisons. A multivariable model was constructed to
determine independent associations including year of dis-
charge, age, sex, primary expected payer, median income by
zip code, hospital region, teaching status, urban/rural loca-
tion, and ischemic stroke admission volume, 29 Elixhauser
comorbid conditions, and the all patient reﬁned-diagnosis
related group measure of disease severity. This model was
used ﬁrst to determine rt-PA use by each race individually at
PSCs versus non-PSCs and then separate models were
constructed for each race, with white patients as the referent
group. Because the introduction of diagnosis-related group
(DRG) 559 in 2006 may have encouraged more accurate
coding for IV tPA use, we also performed a sensitivity analysis
limiting our study population to 2006 and later. Our analytic
models used NIS survey statistics and Taylor series estimation
to account for the survey design and clustering within
hospitals. The analysis was conducted using SAS-callable-
SUDAAN version 11.0.1.
Results
Study Sample
Acute ischemic stroke was the primary diagnosis in 598 606
hospitalizations in the NIS between 2004 and 2010, and of
404,858
Hospitalizations
Exclusion:
Age <18 (n=1,109)
Exclusion:
Hospital not 
identifiable 
(n=192,639)
Exclusion: Admitted as 
transfer (n=25,547)
Exclusion: Unable to determine if 
hospital certified at admission 
(n=1,414)
55,887,443
Hospitalizations
Limit to primary 
diagnosis of acute 
ischemic stroke
598,606
Hospitalizations
597,497
Hospitalizations
304,152 
Hospitalizations in Final 
Dataset
Exclusions: Missing data on 
death, sex, length of stay or 
expected primary payer (n=662)
Exclusion: Unknown race 
(n=73,083)
Figure 1. Flow diagram depicting the patients in the data set,
exclusion criteria, and ﬁnal number of hospitalizations included,
304 152.
Table 2. Elixhauser Comorbidities
AIDS
Alcohol abuse
(Deficiency) anemias
Rheumatoid arthritis
Blood loss anemia
Congestive heart failure
Chronic pulmonary disease
Coagulopathy
Depression
Diabetes (uncomplicated)
Diabetes (w/chronic complications)
Drug abuse
Hypertension
Hypothyroidism
Liver disease
Lymphoma
Fluid and electrolyte disorders
Metastatic cancer
Other neurological disorders
Obesity
Paralysis
Peripheral vascular disorders
Psychoses
Pulmonary circulation disorders
Renal failure
Solid tumor (without metastasis)
Peptic ulcer disease (no bleeding)
Valvular disease
Weight loss
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these 304 152 from 26 states met all eligibility criteria, as
diagrammed in Figure 1.
Demographic Characteristics
Of the 304 152 patients included in the analysis, 75 160
(24.7%) presented to a PSC and 228 992 (75.3%) presented
to a non-PSC. Overall, 71.5% of patients were white, 15.0%
black, 7.9% Hispanic, and 5.6% were in other categories
(Asian/Paciﬁc Islander, Native American, or other). Patient
and hospital characteristics are described in Table 3.
Presentation to PSCs and Intravenous rt-PA Use
Presentation to PSCs occurred for 24.7% of white patients,
27.4% of black patients, 16.2% of Hispanic patients, and
29.8% of patients of other races. A lower proportion of
Hispanic patients were seen at PSCs. Figure 2 shows the
proportion of patients presenting to PSCs over time by race/
ethnicity. For presentation to PSCs, testing for differences
between individual groups (white versus black, white versus
Hispanic, white versus other, black versus Hispanic, black
versus other, and Hispanic versus other) yielded P<0.001. In
total, 3.6% of patients received intravenous rt-PA. Utilization
of rt-PA occurred in 7.1% of patients at PSCs and 2.5% of
patients at non-PSCs. A higher proportion of patients received
rt-PA at PSCs in all racial/ethnic groups compared to
treatment rates at non-PSCs: white patients 7.6% versus
2.6% (P<0.001), black patients 4.8% versus 2.0% (P<0.001),
Hispanic patients 7.1% versus 2.4% (P<0.001), and other
racial groups 7.2% versus 2.5% (P<0.001), as depicted in
Figure 3.
In the unadjusted analysis, the odds of receiving rt-PA
were greater at a PSC versus a non-PSC for all groups
(whites odds ratio (OR)=3.03, 95% CI: 2.65 to 3.45; blacks
OR=2.49, 95% CI: 2.01 to 3.09; Hispanics OR=3.08, 95% CI:
2.40 to 3.94; other races OR=3.05, 95% CI: 2.35 to 3.97).
Increased odds of rt-PA use was further demonstrated in the
fully adjusted analyses (whites OR=1.73, 95% CI: 1.50 to
2.00; blacks OR=1.47, 95% CI: 1.16 to 1.87; Hispanics
OR=1.54, 95% CI: 1.16 to 2.05; other races OR=1.99, 95%
CI: 1.49 to 2.66) as shown in Table 4. Testing for interaction
between race and PSC status for the outcome of rt-PA
treatment, no signiﬁcant effect was demonstrated either in
the crude (P=0.62) or fully adjusted analysis (P=0.98). We
found similar results for the sensitivity analysis limited to
data from 2006 to 2010 (Table 5), the period after the
introduction of DRG559 “Acute ischemic stroke with use of
thrombolytic agent.”
Comparing rt-PA treatment rates between each of the
nonwhite groups and whites showed that individuals in these
racial groups were signiﬁcantly less likely to be treated, after
adjustment for covariates, at both PSCs and non-PSCs
(Table 6). Black patients were signiﬁcantly less likely to be
treated than whites at both PSCs and non-PSCs in both the
unadjusted and fully adjusted models. This trend for black
patients was similar across all subgroups treated at PSCs,
stratiﬁed by sex, age, insurance status, hospital region, and
hospital stroke volume (Figure 4A). Hispanic patients and
patients of other races were as likely to be treated as whites
at PSCs in the unadjusted model but less likely to be treated
in the fully adjusted model (Table 6). Rates of treatment at
PSCs, stratiﬁed across subgroups, are shown for Hispanics
versus whites and other races versus whites (Figure 4B and
4C).
Discussion
Racial and ethnic disparities in stroke are a pressing policy
and public health issue, as minorities are projected to become
a majority of the population in the United States by 2060.33,34
In the present analysis, the proportion of patients receiving rt-
PA was similar in Hispanic patients and white patients.
Hispanic patients presented less frequently to PSCs than
white patients, consistent with a previous report.17 The
disparity in presentation to PSCs persisted throughout the
time period studied. Black patients presented to PSCs at rates
that were similar to white patients, but they were less likely to
receive rt-PA at both PSCs and non-PSCs in both the adjusted
and unadjusted models. Patients in other racial groups
(Hispanic or Asian/Paciﬁc Islander, Native American, and
other) received rt-PA at a rate similar to white patients at both
PSCs and non-PSCs in the unadjusted model, but were less
likely to receive rt-PA after adjusting for covariates.
A greater burden of stroke incidence and mortality for
black and Hispanic patients has been established in the
literature, though reasons for this disparity are unclear.36–39
Few studies have looked at presentation to PSCs by race and
ethnicity.18,40 In the Reasons for Geographic And Racial
Differences in Stroke (REGARDS) study, presentation to PSCs
is similar among black and white patients, though subjects
living in the Stroke Belt states were less likely to be seen at a
PSC.11 PSC access in <60 minutes by ground ambulance is
most available in major cities and access is limited in rural
areas.
The present study demonstrates a difference in utilization
of PSCs for Hispanic patients. Certain factors may play a role
for this minority group, such as the growing rural Hispanic
population or an inability to access the healthcare system for
ﬁnancial or legal reasons in areas where PSCs are readily
available.41 Prior studies have suggested that geographic
areas with a greater proportion of Hispanic individuals are
actually more likely to have access to PSCs,42,43 but realized
access may be lower than geographic access. McDonald et al
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Table 3. Patient and Hospital Characteristics
Patients (%)
Overall Presenting to a PSC Presenting to a Non-PSC
n=304 152 n=75 160 (24.7%) n=228 992 (75.3%)
Race/ethnicity*
White 217 399 (71.5) 53 693 (71.4) 163 706 (71.5)
Black 45 635 (15.0) 12 517 (16.7) 33 118 (14.5)
Hispanic 24 163 (7.9) 3904 (5.2) 20 259 (8.8)
Others† 16 955 (5.6) 5046 (6.7) 11 909 (5.2)
Female* 162 311 (53.4) 39 138 (52.1) 123 173 (53.8)
Age, y*
18 to 44 11 931 (3.9) 3346 (4.5) 8585 (3.7)
45 to 64 76 297 (25.1) 20 170 (26.8) 56 127 (24.5)
≥65 215 924 (71.0) 51 644 (68.7) 164 280 (71.7)
Income‡,§
Lowest quartile 71 340 (23.5) 16 433 (21.9) 54 907 (24.0)
Second quartile 73 584 (24.2) 16 688 (22.2) 56 896 (24.8)
Third quartile 73 348 (24.1) 17 299 (23.0) 56 049 (24.5)
Highest quartile 78 935 (26.0) 23 413 (31.2) 55 522 (24.2)
Missing 6945 (2.3) 1327 (1.8) 5618 (2.5)
Payment type*
Medicare 206 772 (68.0) 49 295 (65.5) 157 513 (68.8)
Medicaid 20 688 (6.8) 4937 (6.6) 15 751 (6.9)
Private, including HMO 57 510 (18.9) 15 735 (20.9) 41 775 (18.2)
Self-pay 11 376 (3.7) 3105 (4.1) 8271 (3.6)
No charge 1676 (0.6) 468 (0.6) 1208 (0.5)
Other 6130 (2.0) 1656 (2.2) 4474 (2.0)
Hospital region*
Northeast 93 858 (30.9) 15 978 (21.3) 77 880 (34.0)
Midwest 31 047 (10.2) 8662 (11.5) 22 385 (9.8)
South 98 603 (32.4) 34 692 (46.2) 63 911 (27.9)
West 80 644 (26.5) 15 828 (21.1) 64 816 (28.3)
Hospital location*
Rural 32 003 (10.5) 2032 (2.7) 29 971 (13.1)
Teaching hospital*
Yes 125 088 (41.1) 43 905 (58.4) 81 183 (35.5)
Ischemic stroke volume, cases/year*
<100 44 119 (14.5) 977 (1.3) 43 142 (18.8)
100 to 299 141 594 (46.6) 24 874 (33.1) 116 720 (51.0)
≥300 118 439 (38.9) 49 309 (65.6) 69 130 (30.2)
HMO indicates health maintenance organization; PSC, Primary Stroke Center.
*Chi-square test between non-PSC and PSC signiﬁcant, P<0.001.
†Others includes Asian/Paciﬁc Islander, Native American, and other.
‡Chi-square test between non-PSC and PSC signiﬁcant, P=0.005.
§Median household income, by ZIP code.
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have shown that hospitals under governmental control were
less likely to acquire PSC certiﬁcation.43 This could dispro-
portionately affect uninsured and underinsured minority
patients.
Our study corroborates ﬁndings of increased rt-PA utiliza-
tion among all race/ethnicities at PSCs. This is consistent
with the ﬁndings of Bhattacharya et al, who performed a chart
review of 5 PSCs and 5 non-PSCs in Michigan and found
improved compliance with core measures for stroke care and
increased use of rt-PA for black patients at stroke centers.40
Our data demonstrate that whereas PSCs treat a higher
proportion of black patients with rt-PA than non-PSCs,
treatment rates in black patients continue to lag behind
other racial and ethnic groups even at these specialty stroke
centers. This ﬁnding is remarkably consistent across sub-
groups stratiﬁed by age, sex, insurance status, hospital
region, and hospital stroke volume.
Trimble and Morgenstern described minority-speciﬁc fac-
tors that contribute to inequalities in access and use of health
services.44 On the patient level, mistrust or misunderstanding
of the healthcare system, poor communication, low income,
and lower education may delay or prevent care. There may be
differences in stroke severity or other rt-PA inclusion/
exclusion criteria across racial groups. Black and Hispanic
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Figure 2. Proportion of stroke patients presenting to PSCs over time, by race/ethnicity.
PSC indicates Primary Stroke Center.
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Figure 3. Proportion of patients receiving rt-PA at non-PSCs and PSCs, by race/ethnicity
(white patients 2.6% vs 7.6%; black patients 2.0% vs 4.8%; Hispanic patients 2.4% vs 7.1%;
other racial groups 2.5% vs 7.2%). PSC indicates Primary Stroke Center; rt-PA, recombinant
tissue plasminogen activator.
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stroke patients present at younger ages,39,45 and younger
patients tend to suffer milder strokes, by National Institutes of
Health Scale.46,47 This could lead to withholding rt-PA
because of either diagnostic uncertainty or a low perceived
likelihood of disability from the presenting symptoms, yet, in 1
multicenter study of young adults with stroke, black patients
suffered worse 30-day mortality and functional outcomes
compared to white patients.48 Mexican-American patients
suffer worse functional outcomes after stroke, despite having
a paradoxical lower mortality and longer survival period,
emphasizing the importance of timely evaluation and treat-
ment in the rapidly growing Hispanic population.49
Table 4. Odds of Receiving rt-PA at a PSC Versus Non-PSC, by Race, in the NIS 2004–2010
Race
Treatment Rate Unadjusted Model 1* Model 2† Model 3‡
PSC (%) Non-PSC (%) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
White 7.60 2.65 3.03 (2.65 to 3.45) 1.81 (1.60 to 2.05) 1.73 (1.50 to 2.00) 1.73 (1.50 to 2.00)
Black 4.76 1.97 2.49 (2.01 to 3.09) 1.63 (1.30 to 2.05) 1.46 (1.15 to 1.85) 1.47 (1.16 to 1.87)
Hispanic 7.07 2.41 3.08 (2.40 to 3.94) 1.77 (1.34 to 2.35) 1.55 (1.17 to 2.05) 1.54 (1.16 to 2.05)
Others§ 7.19 2.48 3.05 (2.35 to 3.97) 2.37 (1.82 to 3.10) 2.00 (1.50 to 2.67) 1.99 (1.49 to 2.66)
APR-DRG indicates all patient reﬁned-diagnosis related group; NIS, Nationwide Inpatient Sample; OR, odds ratio; PSC, Primary Stroke Center; rt-PA, recombinant tissue plasminogen
activator.
*Adjusted for: year, age, sex, primary expected payer, median income quartiles by ZIP code, region, teaching hospital, urban hospital location, and volume of acute ischemic stroke annually
at hospital.
†Model 1+each of the 29 Agency for Healthcare Quality and Research (individual) comorbidities.
‡Model 2+APR-DRG measure of disease severity to estimate the likelihood of dying during the hospitalization (minor, moderate, major, and extreme likelihoods of dying).
§Others includes Asian/Paciﬁc Islander, Native American, and other.
Table 5. Sensitivity Analysis: Odds of Receiving rt-PA at a PSC Versus Non-PSC, by Race, in the NIS 2006–2010
Race
Unadjusted Model 1* Model 2† Model 3‡
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
White 2.52 (2.21 to 2.89) 1.74 (1.54 to 1.96) 1.65 (1.44 to 1.90) 1.66 (1.44 to 1.90)
Black 2.01 (1.61 to 2.51) 1.66 (1.31 to 2.09) 1.52 (1.18 to 1.95) 1.52 (1.18 to 1.97)
Hispanic 2.65 (2.07 to 3.40) 1.80 (1.35 to 2.39) 1.59 (1.19 to 2.13) 1.59 (1.19 to 2.13)
Others§ 2.75 (2.10 to 3.60) 2.49 (1.89 to 3.28) 2.13 (1.55 to 2.94) 2.13 (1.55 to 2.94)
APR-DRG indicates all patient reﬁned-diagnosis related group; NIS, Nationwide Inpatient Sample; OR, odds ratio; PSC, Primary Stroke Center; rt-PA, recombinant tissue plasminogen
activator.
*Adjusted for: year, age, sex, primary expected payer, median income quartiles by ZIP code, region, teaching hospital, urban hospital location, and volume of acute ischemic stroke annually
at hospital.
†Model 1+each of the 29 Agency for Healthcare Quality and Research (individual) comorbidities.
‡Model 2+APR-DRG measure of disease severity to estimate the likelihood of dying during the hospitalization (minor, moderate, major, and extreme likelihoods of dying).
§Others includes Asian/Paciﬁc Islander, Native American, and other.
Table 6. Odds of Receiving rt-PA Compared to Whites, Stratiﬁed by PSC Status, in the NIS 2004–2010
Unadjusted
OR (95% CI)
Fully Adjusted Model*
OR (95% CI)
PSC Non-PSC PSC Non-PSC
Black vs white 0.61 (0.52 to 0.71) 0.74 (0.64 to 0.85) 0.63 (0.54 to 0.74) 0.58 (0.50 to 0.67)
Hispanic vs white 0.92 (0.76 to 1.12) 0.91 (0.76 to 1.09) 0.77 (0.63 to 0.95) 0.75 (0.63 to 0.88)
Others† vs white 0.94 (0.78 to 1.14) 0.93 (0.79 to 1.11) 0.75 (0.64 to 0.89) 0.74 (0.62 to 0.88)
APR-DRG indicates all patient reﬁned-diagnosis related group; NIS, Nationwide Inpatient Sample; OR, odds ratio; PSC, Primary Stroke Center; rt-PA, recombinant tissue plasminogen
activator.
*Multivariable model adjusted for: year, age, sex, primary expected payer, median income quartiles by ZIP code, region, teaching hospital, urban hospital location, volume of acute ischemic
stroke annually at hospital, each of the 29 Agency for Healthcare Quality and Research (individual) comorbidities, and an APR-DRG measure of disease severity to estimate the likelihood of
dying during the hospitalization (minor, moderate, major, and extreme likelihoods of dying).
†Others includes Asian/Paciﬁc Islander, Native American, and other.
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Differences in time to presentation or utilization of EMS
may also underlie differences in rt-PA utilization.50–53 Existing
data on differences in prehospital delays and EMS use are
conﬂicting. Studies in New York City, Minneapolis–St. Paul,
and Houston failed to show differences in delay to emergency
department arrival for black patients.54–57 More recent
studies demonstrated signiﬁcant differences in delay to
arrival within 3 hours22,52,58 that persist after adjusting for
age, sex, stroke severity, and insurance status.26 Boehme
et al found that black women, speciﬁcally, are more likely to
arrive outside of the 3-hour time window than white men,
black men, or white women.59 In their analysis of >200 000
acute stroke cases in the Get With The Guidelines Stroke
registry, Ekundayo et al found that minorities were less likely
to use EMS,12 but in the Greater Cincinnati/Northern
Kentucky Stroke Study there was no difference in EMS
utilization between white and black patients.60 A better
understanding of racial differences in time to presentation and
use of EMS may help to increase our understanding of
modiﬁable risk factors to inform future interventions, with the
ultimate goal of eliminating disparities in stroke care.
Our analysis, which relies on administrative claims data,
has limitations. The NIS coding for race/ethnicity is simpliﬁed
from state-speciﬁc values into 1 of 6 categories used in this
analysis. Though reporting of race has increased over time,
hospitals or Healthcare Cost and Utilization Project State
Partners that do not supply these data were excluded,
including a few states with large minority populations such as
Georgia and Texas. Unknown race was common, likely due to
the data being from hospital discharge information and not
from reporting by the individuals themselves. Although the 26
states that provided data cover roughly 50% of the Hispanic
and black population in the United States, the analysis does
not constitute a nationally representative sample.61,62
Our study deﬁnes PSCs by The Joint Commission certiﬁ-
cation, and does not recognize other national or state-based
certiﬁcations or identify hospitals that participate in national
stroke care improvement programs, such as Get With The
Guidelines. In our analysis, 25 of the 26 states had PSC
hospitals, the exception being Massachusetts, which uses a
state-based certiﬁcation program. Misclassiﬁcation of these
hospitals as nonstroke centers would likely bias our results
toward the null and not change the observed disparities. A
beneﬁt of utilizing administrative data such as the NIS is the
ability to compare hospitals with PSC certiﬁcation to non-PSC
hospitals, even those that have elected not to share data with
a quality improvement initiative or a stroke registry.
Because stroke diagnosis was identiﬁed by International
Classiﬁcation of Diseases, 9th Revision code, clinical informa-
tion on stroke severity, such as the National Institutes of
Health Scale or time of symptom onset, was unavailable for
analysis. Lacking clinical data, we could not ascertain from
Unadjusted
Odds Ratio (95% CI)
All 0.61  (0.52-0.71)
Multivariable Analysis*
Odds Ratio (95% CI)
All 0.63  (0.54-0.74)
Sex
Male 0.62  (0.49-0.78)
Female 0.64  (0.54-0.77)
Age
18-44 years 0.73  (0.54-0.99)
45-64 years 0.72  (0.57-0.90)
65+ 0.57  (0.47-0.68)
Payer
Medicare 0.60  (0.49-0.73)
Medicaid 0.72  (0.48-1.09)
Private [HMO] 0.68  (0.54-0.86)
Self-Pay 0.39  (0.21-0.71)
Hospital Region
Northeast 0.60  (0.46-0.79)
Midwest 0.56  (0.41-0.76)
South 0.65  (0.51-0.83)
West 0.67  (0.51-0.88)
Hospital stroke cases per yr:
100-299 0.74  (0.56-0.97)
300+ 0.61  (0.50-0.74)
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 2.25 2.5
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 2.25 2.5
Unadjusted
Odds Ratio (95% CI)
All 0.92 (0.76-1.12)
Multivariable Analysis*
Odds Ratio (95% CI)
All 0.77  (0.63-0.95)
Sex
Male 0.79 (0.63-1.00)
Female 0.74 (0.55-1.00)
Age
18-44 years 0.69  (0.42-1.12)
45-64 years 0.76 (0.55-1.05)
65+ 0.80 (0.64-1.00)
Payer
Medicare 0.77 (0.60-0.99)
Medicaid 0.83 (0.54-1.29)
Private [HMO] 0.75 (0.53-1.08)
Self-Pay 0.72 (0.36-1.44)
Hospital Region
Northeast 0.53 (0.39-0.72)
Midwest 1.12 (0.48-2.62)
South 0.92 (0.63-1.35)
West 0.78 (0.60-1.03)
Hospital stroke cases per yr:
100-299 0.71 (0.53-0.96)
300+ 0.81 (0.63-1.04)
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 2.25 2.5
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 2.25 2.5
Unadjusted
Odds Ratio (95% CI)
All 0.94  (0.78-1.14)
Multivariable Analysis*
Odds Ratio (95% CI)
All 0.75  (0.64-0.89)
Sex
Male 0.71 (0.58-0.88)
Female 0.78  (0.62-1.00)
Age
18-44 years 0.74 (0.42-1.29)
45-64 years 0.75 (0.57-0.97)
65+ 0.76 (0.62-0.94)
Payer
Medicare 0.73 (0.58-0.93)
Medicaid 0.94 (0.57-1.53)
Private [HMO] 0.76 (0.60-0.96)
Self-Pay 0.59 (0.26-1.32)
Hospital Region
Northeast 0.74 (0.53-1.05)
Midwest 0.73 (0.27-1.97)
South 0.76 (0.58-0.99)
West 0.75 (0.59-0.96)
Hospital stroke cases per yr:
100-299 0.87 (0.66-1.14)
300+ 0.68 (0.56-0.83)
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 2.25 2.5
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 2.25 2.5
A
B
C
Figure 4. Odds of rt-PA use at PSCs for (A) black patients,
(B) Hispanic patients, and (C) Asian/Paciﬁc Islander, Native
American, and other patients, as compared to white patients.
*Excluding the subgroup of interest, adjusted for: year, age,
sex, primary expected payer, median income quartiles by ZIP
code, region, teaching hospital, urban hospital location,
volume of acute ischemic stroke annually at hospital, each of
the 29Agency for Healthcare Quality and Research (individual)
comorbidities, and an APR-DRGmeasure of disease severity to
estimate the likelihood of dying during the hospitalization
(minor, moderate, major, and extreme likelihoods of dying).
APR-DRG indicates all patient reﬁned-diagnosis related group;
HMO, health maintenance organization; PSC, Primary Stroke
Center; rt-PA, recombinant tissue plasminogen activator.
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our analysis the percentage of eligible patients who failed to
receive rt-PA, of any race. As discussed above, there may be
differences in time to arrival, utilization of EMS, and stroke
severity by race. All of these factors may be contributing to
lower rt-PA eligibility and thus lower treatment rates in black
patients. Unfortunately, we are unable to test this hypothesis
and existing literature is conﬂicting.8,22,54–57 Prospective
studies with detailed clinical data are needed to determine
whether racial disparities persist after accounting for rt-PA
eligibility.
International Classiﬁcation of Diseases, 9th Revision pro-
cedure code 99.10 was used to deﬁne rt-PA. This underes-
timates rt-PA use relative to pharmacy billing records,
detecting 77% of rt-PA cases in an analysis of the Get With
The Guidelines data, and has the potential to bias the results if
there are differences in coding across hospitals.63,64 How-
ever, trends showing the increasing use of rt-PA over time are
consistent and ﬁnancial pressures should encourage accurate
coding at all hospitals. The NIS lacks data on Current
Procedural Terminology codes 37201 and 37202, which
might increase sensitivity for rt-PA therapy use.65 Because our
study excludes patients admitted as transfers, we are unable
to investigate “drip and ship” cases, in which rt-PA is
administered in the emergency department of 1 hospital and
then transferred to another hospital. It may be that non-PSCs
are more likely to transfer patients to another hospital after rt-
PA treatment. Excluding transfers avoids incorrectly attribut-
ing these patients to the receiving hospital. However, not
accounting for drip and ship cases may underestimate rt-PA
utilization at non-PSCs and lead us to overestimate the impact
of certiﬁcation.
In conclusion, our analysis provides an overview of
utilization of specialty stroke care and rt-PA administration
among minority patients. While the increasing use of rt-PA
treatment over time is encouraging, efforts still need to be
made to close the gaps in access to PSCs and rt-PA use
across racial and ethnic groups.
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